To deliver the first medical treatment dedicated to patients with haemorrhagic stroke
Sector: Hospital • Location: France
Source: EU Funding & Tenders Portal
The NANOp2lysis platform is a deep-tech technology to protect active enzymes by a reversible precipitation and to produce solid-state nanoparticles. Such particles can then be loaded at high concentration into tailored carrier (with specific targeting / slow delivery characteristics). O2L-001 (derived from NANOp2Lysis) is the first effective and safe treatment to remove intracerebral hematoma and
- Status
- Closed
- Sector
- Hospital
- Location
- France
- Updated
- 22 Jul 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about To deliver the first medical treatment dedicated to patients with haemorrhagic stroke
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | ended |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | The NANOp2lysis platform is a deep-tech technology to protect active enzymes by a reversible precipitation and to produce solid-state nanoparticles. Such particles can then be loaded at high concentration into tailored carrier (with specific targeting / slow delivery characteristics). O2L-001 (derived from NANOp2Lysis) is the first effective and safe treatment to remove intracerebral hematoma and reduce disability and death following acute hemorrhagic stroke (AHS). It has been tailored to be locally injected, after micro-invasive surgery, via a catheter at the core of the hematoma. The in vivo gelation of the product at body temperature allows a local and slow delivery of our new thrombolytic agent, OptPA. The main characteristics of O2L-001 are thus the following: - EASY. simplified model of administration (unique injection) - EFFICIENT. better thrombolytic effect on best translational model (vs gold standard) - SAFE. reduced side effect (bleeding and neurotoxoxicity vs gold standard) |
Location
Country | France |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital |
Article published date | 2025-11-01 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project